Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

24.27 -0.33 (-1.34%)
Streaming Delayed Price Updated: 11:14 AM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives. 
Via Benzinga
Tesla, Avinger, Jet.Ai, Teva, And Netflix: Why These 5 Stocks Are On Investors' Radars Ahead Of Christmas
Wall Street experienced a positive start to the Santa Rally season, with all major indices and sectors closing higher in the session ahead of Christmas. 
Via Benzinga
Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next
Druckenmiller's Duquesne Family Office sold Nvidia and Palantir stocks while increasing stake in Teva Pharmaceutical, signaling a shift in investment focus. 
Via Benzinga
Topics Artificial Intelligence
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025
Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI) stocks in favor of a drugmaker whose shares are up by 112% for the year. 
Via The Motley Fool
Topics Artificial Intelligence
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
My Top 10 Portfolio Holdings for 2025
This combination of growth and value stocks has the potential to outperform the broader market in 2025 (and beyond). 
Via The Motley Fool
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The S&P 500 and Dow Jones Industrial Average dropped by 0.4% and 0.6% respectively, while the Nasdaq 100 declined by 0.3%. 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing. 
Via Investor's Business Daily
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
Teva and Sanofi's Phase 2b RELIEVE UCCD study shows duvakitug improves remission in ulcerative colitis and response in Crohn's disease. 
Via Benzinga
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call today at 8:00 a.m. ET (U.S.) 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Is SoundHound AI a Millionaire-Maker Stock?
Via The Motley Fool
Topics Artificial Intelligence
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
 
Via Benzinga
Teva to Present at the Jefferies London Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
TEVA earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.